miR-200c-3p negatively regulates the expression of occludin in UC patients and in DSS-induced experimental colitis; consequently, antagomiR-200c, an antagonist of miR-200c-3p, inhibited occludin reduction in vitro and in the intestinal tissues of experimental colitis models, preserving the integrity of the TJ barrier [95]. Here, OCLN is linked to colitis.